Single layer oral dose of neuro-attenuating ketamine
US10653629B2 · kind B2 · utility
5Cited by
4References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 31, 2018 |
| Grant date | May 19, 2020 |
| Priority date | — |
| Expiry date | Jan 31, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.